menu

Checkpoint Inhibitor Combination Therapy for First-Line Advanced NSCLC

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Checkpoint Inhibitor Combination Therapy for First-Line Advanced NSCLC

close
ReachMD Healthcare Image
Restart
Resume
Read full article
Choose a format
Media formats available:
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Immunotherapy using checkpoint inhibitors has become a standard of practice in advanced non-small cell lung cancer. But can combination therapy further improve patient outcomes? Dr. Jacob Sands is joined by Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology at Henry Ford Cancer Institute, who recently spoke about this topic at the American Society of Clinical Oncology’s annual meeting.

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Immunotherapy using checkpoint inhibitors has become a standard of practice in advanced non-small cell lung cancer. But can combination therapy further improve patient outcomes? Dr. Jacob Sands is joined by Dr. Shirish Gadgeel, Chief of the Division of Hematology and Oncology at Henry Ford Cancer Institute, who recently spoke about this topic at the American Society of Clinical Oncology’s annual meeting.

Facebook Comments

Programs 9/18/21